Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITY

Weingold et al. (Sat,) studied this question.

www.synapsesocial.com/papers/69a75ed6c6e9836116a29cdb — DOI: https://doi.org/10.1016/j.jdiacomp.2026.109274

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Kidney Disease and Increased Mortality Risk in Type 2 Diabetes· 2013 · 1,253 citations
2. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease· 2024 · 7,250 citations
3. MO462: Change in KDIGO Kidney Risk Category With Semaglutide Treatment—A <i>Post Hoc</i> Analysis of the Sustain 6 Trial· 2022 · 2 citations
4. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts· 2011 · 1,065 citations
5. A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases· 2019 · 878 citations